Navigation Links
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Date:11/28/2007

RIDGEFIELD, Conn., Nov. 28 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., makers of Viramune(R) (nevirapine) tablets, announced today that it has begun to enroll patients in the NEwArT study to include 18 planned sites across the United States. The goal of the NEwArT study is to compare the efficacy and safety of VIRAMUNE, a non-nucleoside reverse transcriptase inhibitor (NNRTI) versus atazanavir, a protease inhibitor (PI) boosted with ritonavir. Both agents will be combined with the fixed dose combination of tenofovir and emtricitabine (Truvada(R)). The NEwArT trial will enroll 150 HIV-positive patients who have not previously been treated with antiretroviral drugs.

"The NEwArT trial may help patients and physicians better understand the role of nevirapine within today's evolving treatment strategies and provide more information on selecting treatment options for first-line therapy in HIV-positive patients," explained lead study investigator Edwin DeJesus, M.D., medical director of the Orlando Immunology Center.

The NEwArT (efficacy and safety of NEvirapine compared With Atazanavir boosted with Ritonavir and a background of Truvada in HIV-1 infected patients who have received no previous antiretroviral treatment) study is a Phase IV, open-label, randomized, multicenter trial with a primary endpoint of virologic response at 48 weeks, defined as a viral load <50 copies/mL at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral therapy by Week 48. Secondary endpoints will include an evaluation of change in fasting lipids.

Patients will be randomized to receive either 200 mg of VIRAMUNE twice daily or 300 mg of atazanavir boosted with 100 mg of ritonavir once daily. Patients in the VIRAMUNE arm will begin their treatment with 200 mg once daily increased to 200 mg twice daily after two weeks. The current VIRAMUNE CD4+ cell criteria are being applied to both arms of the study. All pati
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster of ... May 18, in Santa Monica, Calif. ... lung-sparing therapies for MPM, a rare form of cancer ... the pleura, the lining of the chest. ... Blood Institute, the 3rd Annual International Symposium on Lung-Sparing ...
(Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer").  On 20 May 2013, Royalty Pharma ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... division of Wyeth (NYSE: WYE ), presented ... showed that bazedoxifene/conjugated,estrogens reduced the number and severity ... to 80 percent, when compared with placebo. These,data, ... Meeting,also showed that bazedoxifene/conjugated estrogens improved symptoms of,vulvar ...
... study published in the Oct. 1,Journal of Nutrition suggests ... the risk of prostate cancer, Solae notes, giving consumers ... The study, "Soy protein isolate increases urinary estrogens ... risk of prostate cancer,",is believed to be the first ...
Cached Medicine Technology:Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 2Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 4Study Suggests Soy Protein May Reduce Prostate Cancer Risk 2
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...
(Date:5/24/2013)... CBT News.com recently announced the addition of ... retail automotive industry news organization with 12 years experience in ... join a group that’s so forward-thinking in their approach,” says ... video content is on the rise.” , Atlanta born and ... segued into advertising at Cycle News and Boating World. He ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... recommended well-child visits had up to twice the risk ... their visits, according to a study published today in ... study included more than 20,000 children enrolled at Group ... asthma and heart disease were even more likely to ... study. In fact, children with chronic conditions who ...
Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3
... Brand Innovation is offering a custom e-book, "Notes on Nursing" by Florence ... e-book is one in a series of e-books titled I ... C la s s i ... http://www.stinsonbrandinnovation.com/ebooks/SBI_NotesOnNursing.htm , "This is a way we celebrate the vital ...
... survey also finds unique mix of bacteria for each person ... "atlas" of bacterial life on and within the human body ... are a veritable United Nations of germs. , The scientists, ... they like to thrive on and within the body. They ...
... Picture it: One jerk in a bar spends the night ... the evening, the women aren,t receptive to even the nicest ... evolutionary theory. Males increase their fitness by acquiring more mates; ... and therein lies the conflict. Researchers at Binghamton University ...
... mimic parents, language, study finds , THURSDAY, Nov. 5 ... days old cry with intonation patterns that reflect the ... The conclusion drawn by German researchers is that fetuses ... trimester of pregnancy, laying the groundwork for learning language ...
... Seats still ... ... economy recovers from the recession, the province’s health care sector is just one industry taking ... the field and an increased need for nursing care from the province’s aging population. Anyone ...
... House Rules Committee announced that the "rule" for ... put forward by Rep. Brad Ellsworth, D-Ind. that the House ... language, House Democratic leaders hope to address the reluctance of ... , Dr. Charmaine Yoest, President and CEO of ...
Cached Medicine News:Health News:National Nurse Practitioner Week Recognized by STINSON Brand Innovation With Offer of 'Notes on Nursing' e-book 2Health News:Germs Mingle Most on Palms, Feet, Forearms 2Health News:Germs Mingle Most on Palms, Feet, Forearms 3Health News:Mom was right: Nice guys don't always finish last 2Health News:Fetus Learns Intonations of Mother's Tongue 2Health News:Fetus Learns Intonations of Mother's Tongue 3Health News:Practical Nursing Still a Growth Area in BC 2
... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...
Inquire...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
Medicine Products: